Compare BL & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BL | TSHA |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2016 | 2020 |
| Metric | BL | TSHA |
|---|---|---|
| Price | $32.81 | $5.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $56.62 | $11.63 |
| AVG Volume (30 Days) | 971.7K | ★ 2.1M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $177,031,000.00 | $9,773,000.00 |
| Revenue This Year | $12.62 | N/A |
| Revenue Next Year | $10.90 | $1,152.42 |
| P/E Ratio | $84.20 | ★ N/A |
| Revenue Growth | ★ 43.78 | 17.28 |
| 52 Week Low | $24.70 | $2.72 |
| 52 Week High | $59.57 | $7.30 |
| Indicator | BL | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 38.99 |
| Support Level | $27.74 | $5.28 |
| Resistance Level | $34.09 | $6.01 |
| Average True Range (ATR) | 1.34 | 0.28 |
| MACD | 0.14 | -0.07 |
| Stochastic Oscillator | 81.42 | 0.50 |
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.